, Volume 8, Issue 1, pp 229–236 | Cite as

Synthesis Characterization and In Vitro Release Study of Ciprofloxacin-Loaded Chitosan Nanoparticle

  • Kushagri Singh
  • Abha Mishra
  • Amit Singh


Ciprofloxacin, a poorly soluble drug-loaded chitosan nanoparticle, was prepared for the treatment of microbial infections. Nanoformulation of ciprofloxacin was prepared using 85% deacetylated chitosan as a biodegradable polymer and tripolyphosphate (TPP) as a cross-linking agent by ionotropic gelation. It was further evaluated and characterized on the basis of morphology, drug loading efficiency, X-ray diffraction, zeta potential value, Fourier transform infrared study, antimicrobial study, and also in vitro release behavior of ciprofloxacin. The FTIR spectral studies indicated that there was no interaction found between the drug and chitosan. The sample CS1 formulation was found stable with good drug entrapment efficiency, fair zeta potential value, and its size ranged between 100 and 200 nm. The in vitro study showed sustained release behavior with steady rise in cumulative drug release (> 99%) for up to about 8 h and thereafter, no significant release observed. The characterized formulations were also used to study antimicrobial activity.


Nanoformulation Ciprofloxacin Zeta potential Biodegradable polymer Microbial infection 



The authors would like to acknowledge the financial support from the Department of Science & Technology-INSPIRE fellowship, New Delhi, India. Prof. R.K.Mandal (Department of Metallurgical Engineering, IIT, BHU, Varanasi) for providing SEM facility, CISF, IIT,BHU for providing XRD facility & S.K. Singh (Department of pharmaceutics, IIT, BHU, VARANASI) for providing zeta potential and FTIR facility.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Wu, G., Wang, G., Fu, X., & Zhu, L. (2003). Synthesis, crystal structure, stacking effect and antimicrobial studies of novel quaternary copper (II) complex with quinolone. Molecules, 8, 287–296.CrossRefGoogle Scholar
  2. 2.
    LG, S., & WN, K. (1997). Development of ciprofloxacin: the USA perspective. In W. APR & R. N. Gruneberg (Eds.), Ciprofloxacin: 10 years of clinical experiences (pp. 1–5). Oxford: Published by Maxim Medical.Google Scholar
  3. 3.
    British Pharmacopia (BP). (2009). (493). London: The stationary office; 493.Google Scholar
  4. 4.
    Blondeau, J. M. (2004). Fluoroquinolones: Mechanism of action, classification, and development of resistance. Survey of Ophthalmology, 49(2), S73–S78.CrossRefGoogle Scholar
  5. 5.
    Wilhelmus, K. R., Hyndiuk, R. A., Caldwell, D. R., Abshire, R. L., Folkens, A. T., & Godio, L. B. (1993). 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The ciprofloxacin ointment/bacterial keratitis study group. Archives of Ophthalmology, 11, 1210–1218.CrossRefGoogle Scholar
  6. 6.
    Acar, J. F., & Goldstein, F. W. (1997). Trends in bacterial resistance to fluoroquinolones. Clinical Infectious Diseases, 24(1), S67–S73.CrossRefGoogle Scholar
  7. 7.
    Huneault, L. M., Lussier, B., Dubreuil, P., Chouinard, L., & Désévaux, C. (2004). Prevention and treatment of experimental osteomyelitis in dogs with ciprofloxacin-loaded crosslinked high amylose starch implants. Journal of Orthopaedic Research, 22(6), 1351–1357.CrossRefGoogle Scholar
  8. 8.
    Mehnert, W., & Mader, K. (2001). Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews, 47(2–3), 165–196.CrossRefGoogle Scholar
  9. 9.
    McCarron, P. A., & Hall, M. (2008). International Journal of Pharmaceutics, 348, 115–124.CrossRefGoogle Scholar
  10. 10.
    Goya, S., Rai, J. K., Narang, R. K., & Rajesh, K. S. (2010). International Journal of Pharmacy and Pharmaceutical Sciences, 2(2), 1–6.Google Scholar
  11. 11.
    Gunatillake, P. A., & Adhikari, R. (2003). European Cells and Materials, 5, 1–16.CrossRefGoogle Scholar
  12. 12.
    Lam, X. M., Duenas, E. T., Daugherty, A. L., Levin, N., & Cleland, J. L. (2000). Journal of Controlled Release, 67, 281–292.CrossRefGoogle Scholar
  13. 13.
    Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, L. H., & Langer, R. (1991). Pharmaceutical Research, 8, 713–720.CrossRefGoogle Scholar
  14. 14.
    Thanou, M., Verhoef, J. C., & Junginger, H. E. (2001). Chitosan and its derivatives as intestinal absorption enhancers. Advanced Drug Delivery Reviews 50 Suppl, 1, S 91–S101.CrossRefGoogle Scholar
  15. 15.
    Suri, S. S., Fenniri, H., & Singh, B. (2007). Nanotechnology-based drug delivery systems. Journal of Occupational Medicine and Toxicology, 2, 1–6. 6673-2-1.CrossRefGoogle Scholar
  16. 16.
    Calvo, P., Remuan-Lopez, C., Vila-Jato, J., & Alonso, M. (1997). Journal of Applied Polymer Science, 125132, 63.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.School of Biochemical Engineering, Indian Institute of TechnologyBanaras Hindu UniversityVaranasiIndia
  2. 2.Institute of Medical SciencesBanaras Hindu UniversityVaranasiIndia

Personalised recommendations